A. Sinclair Dunlop - Net Worth and Insider Trading
A. Sinclair Dunlop Net Worth
The estimated net worth of A. Sinclair Dunlop is at least $8 Million dollars as of 2024-12-28. A. Sinclair Dunlop is the Director of Apellis Pharmaceuticals Inc and owns about 247,526 shares of Apellis Pharmaceuticals Inc (APLS) stock worth over $8 Million. Details can be seen in A. Sinclair Dunlop's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that A. Sinclair Dunlop has not made any transactions after 2024-09-16 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of A. Sinclair Dunlop
A. Sinclair Dunlop Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, A. Sinclair Dunlop owns 1 companies in total, including Apellis Pharmaceuticals Inc (APLS) .
Click here to see the complete history of A. Sinclair Dunlop’s form 4 insider trades.
Insider Ownership Summary of A. Sinclair Dunlop
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| APLS | Apellis Pharmaceuticals Inc | 2024-09-16 | director |
A. Sinclair Dunlop Latest Holdings Summary
A. Sinclair Dunlop currently owns a total of 1 stock. A. Sinclair Dunlop owns 247,526 shares of Apellis Pharmaceuticals Inc (APLS) as of September 16, 2024, with a value of $8 Million.
Latest Holdings of A. Sinclair Dunlop
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| APLS | Apellis Pharmaceuticals Inc | 2024-09-16 | 247,526 | 32.68 | 8,089,150 |
Holding Weightings of A. Sinclair Dunlop
A. Sinclair Dunlop Form 4 Trading Tracker
According to the SEC Form 4 filings, A. Sinclair Dunlop has made a total of 18 transactions in Apellis Pharmaceuticals Inc (APLS) over the past 5 years, including 0 buys and 18 sells. The most-recent trade in Apellis Pharmaceuticals Inc is the sale of 37,000 shares on September 16, 2024, which brought A. Sinclair Dunlop around $1 Million.
Insider Trading History of A. Sinclair Dunlop
- 1
A. Sinclair Dunlop Trading Performance
A. Sinclair Dunlop Ownership Network
A. Sinclair Dunlop Owned Company Details
What does Apellis Pharmaceuticals Inc do?
Who are the key executives at Apellis Pharmaceuticals Inc?
A. Sinclair Dunlop is the director of Apellis Pharmaceuticals Inc. Other key executives at Apellis Pharmaceuticals Inc include See Remarks Jeffrey Eisele , General Counsel David O. Watson , and See Remarks James George Chopas .
Apellis Pharmaceuticals Inc (APLS) Insider Trades Summary
Over the past 18 months, A. Sinclair Dunlop made 6 insider transaction in Apellis Pharmaceuticals Inc (APLS) with a net sale of 149,575. Other recent insider transactions involving Apellis Pharmaceuticals Inc (APLS) include a net sale of 284,688 shares made by Pascal Deschatelets , a net sale of 433,087 shares made by Cedric Francois , and a net sale of 33,060 shares made by Timothy Eugene Sullivan .
In summary, during the past 3 months, insiders sold 5,063 shares of Apellis Pharmaceuticals Inc (APLS) in total and bought 0 shares, with a net sale of 5,063 shares. During the past 18 months, 1,149,235 shares of Apellis Pharmaceuticals Inc (APLS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 1,149,235 shares.
Apellis Pharmaceuticals Inc (APLS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Apellis Pharmaceuticals Inc Insider Transactions
A. Sinclair Dunlop Mailing Address
Above is the net worth, insider trading, and ownership report for A. Sinclair Dunlop. You might contact A. Sinclair Dunlop via mailing address: C/o Apellis Pharmaceuticals, Inc., 6400 Westwind Way, Suite A, Crestwood Ky 40014.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
